Modelling the anti-migraine effects of BIBN 4096 BS: A new calcitonin gene-related peptide receptor antagonist

Clinical Pharmacokinetics

Volumn 45, Issue 7, 2006, Pages 715-728

  Trocóniz, Iñaki F ^a   Wolters, Jan Markus ^b   Tillmann, Christiane ^b   Schaefer, Hans G ^b   Roth, Willy ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; OLCEGEPANT;

ADULT; ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; HEADACHE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MIGRAINE; POPULATION MODEL; PRIORITY JOURNAL;

ADULT; AGED; ALGORITHMS; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DIPEPTIDES; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MODELS, STATISTICAL; NONLINEAR DYNAMICS; POPULATION; QUINAZOLINES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; RECEPTORS, DRUG; SOFTWARE;

EID: 33745626160     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645070-00006     Document Type: Article

References (33)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 Jul-Aug; 41 (7): 646-57
2. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive, peptide levels in the plasma of young migraine patients with or without aura assessed both interictally and ictally. Cephalalgia 1995 Oct; 15 (5): 384-96
3. Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996 Aug; 16 (5): 310-6
4. Durham PL. CGRP-receptor antagonists: a fresh approach to migraine therapy? N Engl J Med 2004 Mar; 350 (11): 1073-5
5. Buzzi MG, Carter WB, Shimizu T, et al. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagital sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991 Nov; 30 (11): 1193-200
6. de Hoon JN, Willigers JM, Troost J, et al. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 2000 Oct; 68 (4): 418-26
7. Schindler M, Doods HN. Binding properties of the novel, non-peptide CGRP receptor anatgonist radioligand, [(3)H] BIBN 4096 BS]. Eur J Pharmacol 2002 May; 442 (3): 187-93
8. Doods H. Development of CGRP antagonists for the treatment of migraine. Curr Opin Investig Drugs 2001 Sep; 2 (9): 1261-8
9. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004 Mar; 350 (11): 1104-10
10. Iovino M, Feifel U, Yong CL, et al. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia. 2004 Aug; 24 (8): 645-56
11. Trocóniz IF, Wolters JM, Schaefer HG, et al. Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists. Eur J Pharm Sci 2004 Jul; 22 (4): 287-95
12. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67-95
13. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1S-96S
14. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat Med 1995 May; 14 (9-10): 911-22
15. Roon KI, Olesen J, Diener HC, et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol 2000 Feb; 47 (2): 238-41
16. Beal SL, Sheiner LB, editors. NONMEM users' guides. San Francisco (CA): NONMEM Project Group, University of California at San Francisco, 1992
17. Sheiner LB. A new approach to the analysis of the analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther 1994 Sep; 56 (3): 309-22
18. Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996 Dec; 60 (6): 619-35
19. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm 1992 Oct; 20 (5): 511-28
20. Jonsson EN, Karlsson MO. Xpose: an Splus based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999 Jan; 58 (1): 51-64
21. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979 Mar; 25 (3): 358-71
22. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993 Aug; 21 (4): 457-78
23. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001 Apr; 28 (2): 171-92
24. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980
25. Visser SA, Huntjens DRH, Van der Graff PH, et al. Mechanism-based modeling of the pharmacodynamic intercation of alphaxalone and midazolam in rats. J Pharm Exp Ther 2003 Nov; 307 (2): 765-75
26. Nestorov I, Graham G, Duffull S, et al. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm Res 2001 Aug; 18 (8): 1210-9
27. Jusko WJ, Ko HC, Ebling WF. Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm 1995 Feb; 23 (1): 5-8
28. Tfelt-Hansen P, Paalzow L. Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther 1985 Jan; 37 (1): 29-35
29. Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003 Feb; 30 (1): 83-103
30. Allen C, Jiang K, Malbecq W, et al. Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology. Cephalagia 1999 Jul; 19 (6): 552-6
31. Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol 1990 Sep; 30 (3): 405-9
32. Troconiz IF, Armenteros S, Planelles MV, et al. Pharmacokinetic- Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. Clin Pharmacokinet 2000 Jun; 38 (6): 505-18
33. Lindberg-Freijs A, Karlsson MO. Dose dependent absorption and linear disposition of cyclosporin A in rat. Biopharm Drug Dispos 1994 Jan; 15 (1): 75-86